J. Safra Sarasin Holding AG Purchases 4,371 Shares of Hologic, Inc. $HOLX

Key Points

• J. Safra Sarasin Holding AG increased its stake in Hologic, Inc. by 55.3% during the second quarter, acquiring an additional 4,371 shares, bringing its total holdings to 12,280 shares valued at $800,000.
• Multiple analysts have raised their target prices for Hologic, with UBS increasing it from $65 to $70 and Argus raising it from $80 to $90, indicating a positive outlook for the stock.
• CEO Stephen P. Macmillan sold 138,358 shares of Hologic stock for over $9 million, reducing his ownership by 10.08%, though he still retains a significant stake valued at approximately $82.7 million.

J. Safra Sarasin Holding AG grew its position in Hologic, Inc. (NASDAQ:HOLX - Free Report) by 55.3% during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 12,280 shares of the medical equipment provider's stock after purchasing an additional 4,371 shares during the quarter. J. Safra Sarasin Holding AG's holdings in Hologic were worth $800,000 as of its most recent SEC filing.

A number of other institutional investors also recently modified their holdings of the company. Greenleaf Trust raised its position in shares of Hologic by 5.1% in the second quarter. Greenleaf Trust now owns 3,579 shares of the medical equipment provider's stock valued at $233,000 after purchasing an additional 173 shares during the period. Beverly Hills Private Wealth LLC boosted its stake in Hologic by 3.6% during the 1st quarter. Beverly Hills Private Wealth LLC now owns 5,173 shares of the medical equipment provider's stock valued at $320,000 after purchasing an additional 180 shares during the period. Allworth Financial LP boosted its stake in Hologic by 46.0% during the 1st quarter. Allworth Financial LP now owns 686 shares of the medical equipment provider's stock valued at $40,000 after purchasing an additional 216 shares during the period. First American Bank boosted its stake in Hologic by 0.9% during the 2nd quarter. First American Bank now owns 28,705 shares of the medical equipment provider's stock valued at $1,870,000 after purchasing an additional 245 shares during the period. Finally, Integrated Advisors Network LLC boosted its stake in Hologic by 5.4% during the 1st quarter. Integrated Advisors Network LLC now owns 5,603 shares of the medical equipment provider's stock valued at $346,000 after purchasing an additional 289 shares during the period. Institutional investors own 94.73% of the company's stock.

Wall Street Analysts Forecast Growth

Several analysts recently weighed in on the company. UBS Group increased their target price on Hologic from $65.00 to $70.00 and gave the company a "neutral" rating in a research note on Thursday, July 31st. Wall Street Zen downgraded Hologic from a "buy" rating to a "hold" rating in a research note on Wednesday. Stephens restated an "overweight" rating and set a $78.00 target price on shares of Hologic in a research note on Thursday, September 18th. Evercore ISI increased their target price on Hologic from $62.00 to $68.00 and gave the company an "in-line" rating in a research note on Tuesday, July 8th. Finally, Argus increased their target price on Hologic from $80.00 to $90.00 and gave the company a "buy" rating in a research note on Friday, September 19th. One equities research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating and nine have given a Hold rating to the stock. According to MarketBeat, Hologic presently has an average rating of "Moderate Buy" and an average price target of $79.38.

Insiders Place Their Bets

In related news, CEO Stephen P. Macmillan sold 138,358 shares of the firm's stock in a transaction on Monday, September 22nd. The stock was sold at an average price of $66.97, for a total transaction of $9,265,835.26. Following the completion of the sale, the chief executive officer directly owned 1,234,624 shares of the company's stock, valued at $82,682,769.28. This trade represents a 10.08% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. 1.88% of the stock is owned by corporate insiders.

Hologic Trading Up 0.5%

HOLX stock opened at $68.22 on Friday. The business has a fifty day moving average price of $66.97 and a 200 day moving average price of $63.09. Hologic, Inc. has a fifty-two week low of $51.90 and a fifty-two week high of $84.39. The stock has a market capitalization of $15.17 billion, a price-to-earnings ratio of 28.31, a P/E/G ratio of 2.34 and a beta of 0.63. The company has a debt-to-equity ratio of 0.52, a current ratio of 3.55 and a quick ratio of 2.81.

Hologic (NASDAQ:HOLX - Get Free Report) last released its quarterly earnings results on Wednesday, July 30th. The medical equipment provider reported $1.08 earnings per share for the quarter, beating analysts' consensus estimates of $1.05 by $0.03. Hologic had a return on equity of 19.69% and a net margin of 13.79%.The firm had revenue of $1.02 billion during the quarter, compared to analysts' expectations of $1.01 billion. During the same period last year, the firm posted $1.06 EPS. The business's revenue was up 1.2% on a year-over-year basis. Hologic has set its Q4 2025 guidance at 1.090-1.120 EPS. FY 2025 guidance at 4.230-4.260 EPS. Analysts expect that Hologic, Inc. will post 4.28 EPS for the current fiscal year.

Hologic Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.

Want to see what other hedge funds are holding HOLX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Hologic, Inc. (NASDAQ:HOLX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.